| Variable |
No of patients |
% of total |
| Age, years (median, 61 years)
≤ 60
>60 |
11
13 |
45.8%
54.2% |
| Performance status
ECOG 0
ECOG 1-2 |
20
5 |
83.4%
16.6% |
| Menopausal status
Pre-
Post- |
7
17 |
29.2%
70.8% |
| Tumour histology
Ductal carcinoma
Lobular carcinoma
Other |
20
2
2 |
83.4%
8.3%
8.3% |
| Histologic grade
G1-G2
G3 |
6
18 |
25%
75% |
| Ki-67 (median 60%)
≤ 20%
>20% |
7
17 |
29.2%
70.8% |
| Lympho-vascular invasion
Yes
No |
9
15 |
37.5%
62.5% |
| Necrosis
Yes
No |
5
19 |
20.8%
79.2% |
| AR
Positive
Negative |
8
16 |
33%
67% |
| Type of surgery
Quadrantectomy
Radical mastectomy |
10
14 |
41.7%
58.3% |
| (Neo)adjuvant chemotherapy
CMF/CMFLike
Antracyclines
Antracyclines and taxanes
No |
5
8
10
1 |
20.8%
33%
41.7%
4.5% |
| Visceral disease
Yes
No |
19
5 |
7.2%
20.8% |
| Number of metastatic sites
<3
≥ 3 |
16
8 |
67%
33% |
| First-line chemotherapy
Antracyclines-based
Taxanes-based
Platinum-based
Other |
5
12
6
6 |
20.8%
50%
33%
33% |
| First-line chemotherapy
Single-agent
Combination of drugs |
10
14 |
41.7%
58.3% |
